Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

MLA

Bachelot, Thomas, et al. “Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 32, Nov. 2022, pp. 3699–708. EBSCOhost, https://doi.org/10.1200/JCO.21.02179.

APA

Bachelot, T., Cottu, P., Chabaud, S., Dalenc, F., Allouache, D., Delaloge, S., Jacquin, J.-P., Grenier, J., Venat Bouvet, L., Jegannathen, A., Campone, M., Del Piano, F., Debled, M., Hardy-Bessard, A.-C., Giacchetti, S., Mouret-Reynier, M.-A., Barthelemy, P., Kaluzinski, L., Mailliez, A., … Andre, F. (2022). Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(32), 3699–3708. https://doi.org/10.1200/JCO.21.02179

Chicago

Bachelot, Thomas, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, et al. 2022. “Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40 (32): 3699–3708. doi:10.1200/JCO.21.02179.